Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma

Progression of cancer is often associated with interactions between cancer cells and extracellular matrix(ECM) surrounding them. Increasing evidence has suggested that accumulation of hyaluronan(HA), a major component of ECM, provides a favorable microenvironment for cancer progression. Pancreatic d...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmaceutica Sinica. B 2016-03, Vol.6 (2), p.101-105
Main Authors: Sato, Norihiro, Cheng, Xiao-Bo, Kohi, Shiro, Koga, Atsuhiro, Hirata, Keiji
Format: Article
Language:English
Subjects:
4-Methylumbelliferone
adenocarcinoma
Hyaluronan
Tumor
Desmoplasia
ductal
Hyaluronan
interaction
Therapeutic
Pancreatic
Pancreatic ductal    adenocarcinoma
PEGPH20
Review
stroma
Desmoplasia
Tumor–stromal
target
4-Methylumbelliferone
PEGPH20
Therapeutic target
Tumor stroma
Tumor–stromal    interaction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Progression of cancer is often associated with interactions between cancer cells and extracellular matrix(ECM) surrounding them. Increasing evidence has suggested that accumulation of hyaluronan(HA), a major component of ECM, provides a favorable microenvironment for cancer progression. Pancreatic ductal adenocarcinoma(PDAC) is characterized typically by a dense desmoplastic stroma with a large amount of HA, making this molecule as an attractive target for therapy. Several studies have shown efficacy of inhibitors of HA synthesis or signaling for the treatment of PDAC. Recent studies have also demonstrated substantial improvements in the effects of chemotherapy by a targeted depletion of stromal HA in PDAC using an enzymatic agent. Thus, targeting HA has been recognized as a promising therapeutic strategy to treat this highly aggressive neoplasm. In this review article, we summarize our current understanding of the role of HA in the progression of PDAC and discuss possible therapeutic approaches targeting HA.
ISSN:2211-3835
2211-3843
DOI:10.1016/j.apsb.2016.01.002